Odylia speaks to Xconomy about our plan to resurrect stranded gene therapies

Odylia co-founders Scott Dorman and Luk Vandenberghe speak to Xconomy about the problems keeping gene therapies for rare disease from reaching patients. In this article, Dorfman and Vandenberghe speak about the dozens, if not hundreds, of inherited retinal dystrophies that could be amenable to treatment by gene therapy, and Odylia’s plan to move those therapies into patients.

Read Article